T&R Biofab Co Ltd

T&R Biofab has a price-to-book ratio of 5.58 and a price-to-tangible-book ratio of 5.58, indicating that the market is valuing the company at a premium to its book value. The enterprise value to revenue ratio is also 5.58, suggesting that the company is being valued at a multiple of its revenue, despite reporting a net loss of 34,944,025,170 KRW in the latest period. The company's liquidity position is characterized by a current ratio of 1.09 and a debt-to-equity ratio of 1.28, with long-term debt amounting to 29,562,311,850 KRW and cash and equivalents of 7,760,524,310 KRW. The company's profitability is weak, with a return on equity of -1.5142 and a return on assets of -0.3769, both significantly below the industry median for medical equipment and supplies. The operating loss of 11,752,134,110 KRW and a net loss of 34,944,025,170 KRW indicate a challenging operating environment, with gross profit of 6,879,655,200 KRW insufficient to cover operating expenses. T&R Biofab's revenue is derived from the sale of bioresorbable scaffolds, 3D biodegradable polymer printing systems, bioinks, 3D organoids, and 3D cell therapies. The company operates in both domestic and international markets, but the input data does not provide specific revenue concentration by segment or geography. The company's growth trajectory is uncertain, with no specific revenue growth or decline percentages provided in the input data. However, the negative operating and net income suggest a lack of profitability, and the free cash flow of -32,312,012,800 KRW indicates that the company is not generating sufficient cash to fund operations or expansion. The risk assessment for T&R Biofab highlights a medium liquidity risk, with a negative net cash position after subtracting total debt. The dilution risk is assessed as low, and the company has not issued additional shares recently. The negative operating cash flow of -7,465,731,900 KRW and the capital expenditure of -2,401,565,320 KRW further underscore the company's financial challenges. Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The latest actual EPS is -440.22 KRW, and the latest actual revenue is 3,251,050,000 KRW, both indicating a continued period of financial underperformance.